SAS Integrates JMP® Software with Ingenuity Pathways Analysis
News Feb 20, 2007
SAS and Ingenuity Systems have announced a partnership aimed at streamlining the discovery of important biological connections from high-throughput microarray experiments.
Integration between JMP Genomics software from SAS and Ingenuity Pathways Analysis (IPA) provides users the capability to upload the results of microarray analysis workflows directly into IPA for interpretation of their experimental data within a biological context.
JMP Genomics combines the visualization and analytic flexibility of the SAS® and JMP statistical platforms with prebuilt analytics for large genetics, microarray and spectral data sets.
“JMP Genomics is used by biologists and biostatisticians to identify and explore statistically relevant patterns in large expression data sets,” explained Shannon Conners, JMP Genomics Product Manager.
“We are pleased to offer our mutual users a smooth transition from high-quality statistical discovery to biological discovery through integration with the Ingenuity Pathways Analysis solution,” said Conners.
“By integrating Ingenuity Pathway Analysis with JMP Genomics, our joint customers will have a robust and reliable solution for analyzing and interpreting their data,” said Tuan Nguyen, Vice President, Partner and Professional Services of Ingenuity Systems.
Nguyen further said, “The integration supports a unified workflow that enables users to seamlessly analyze data and generate results that are biologically relevant so they can make informed research decisions. Ingenuity Systems has the leading database in the industry for biological information, and through IPA, JMP Genomics users can benefit from this information to uncover mechanisms of action, predict potential toxicities and identify candidate biomarkers.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.